Age, Blasts, Performance Status and Lenalidomide Therapy Influence the Outcome of Myelodysplastic Syndrome With Isolated Del(5q): A Study of 58 South American Patients
- 25 July 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (1), e1-e6
- https://doi.org/10.1016/j.clml.2021.07.026
Abstract
No abstract availableFunding Information
- Consejo Nacional de Investigaciones Científicas y Técnicas (PIP 0056, 1623, PICT 0480)
- Agencia Nacional de Promoción Científica y Tecnológica (PIP 0056, 1623, PICT 0480)
This publication has 14 references indexed in Scilit:
- p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)Haematologica, 2014
- Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomideAnnals of Hematology, 2014
- Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter studyLeukemia, 2012
- TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease ProgressionJournal of Clinical Oncology, 2011
- Advances in the 5q− syndromeBlood, 2010
- WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutationsLeukemia, 2010
- Dysgranulopoiesis is an independent adverse prognostic factor in chronic myeloid disorders with an isolated interstitial deletion of chromosome 5qLeukemia, 2008
- Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q DeletionThe New England Journal of Medicine, 2006
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006
- Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid MalignanciesClinical Cancer Research, 2006